Brokerage firm Choice Institutional Equities has reiterated a 'Buy' rating on Yatharth Hospitals with a target price of Rs 1,100, citing an ambitious bed expansion strategy. While the company recently reported strong revenue growth in the first quarter of FY27, investors are closely watching margin trends and the impact of heavy capital investment on short-term profits.
Choice Institutional Equities has maintained its positive outlook on Yatharth Hospital & Trauma Care Services, setting a target price of Rs 1,100 per share. The brokerage highlighted the hospital chain's growth strategy, which aims to reach a capacity of 5,000 beds within the next three years. This expansion plan, involving both brownfield projects and strategic acquisitions, forms the basis of the firm's optimism regarding the company’s long-term business trajectory.
Q1 FY27 Performance and Growth
The brokerage's report comes shortly after the company released its financial results for the first quarter of the 2026-27 financial year. Yatharth Hospitals reported a consolidated revenue of Rs 3,927 million, marking a 51% year-on-year increase. However, the profit after tax stood at Rs 454 million, an 8% growth compared to the same period last year. This gap between high revenue growth and more modest profit growth highlights the current pressure on profit margins, largely driven by higher depreciation and interest costs associated with new hospital facilities.
Expansion and Operational Risks
While the expansion plan is a primary driver for the brokerage's target price, it also brings specific risks that investors should monitor. Rapid addition of beds and the integration of new facilities carry execution risks, which can impact cash flow and operational stability. Additionally, a significant portion of the company’s revenue—approximately 40%—is dependent on government-sponsored healthcare schemes. This reliance can limit the company's ability to adjust pricing, potentially impacting overall margins if cost pressures rise or if reimbursement rates do not keep pace with inflation.
Dividends and Future Monitorables
On August 10, 2026, the company’s board approved its first interim dividend of Rs 0.50 per share for the fiscal year 2026-27, reflecting a commitment to rewarding shareholders despite the heavy spending on expansion. Moving forward, the key factor for investors will be how effectively the company can improve occupancy rates and operating margins as these new units start their operations. Investors may want to track the actual timeline of bed additions and whether the company can maintain its profitability metrics while aggressively scaling its business.